Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (31-40 of 189) with videos related to

Pageof 19
Sort By:
European Journal of Clinical Pharmacology|May 14, 2010
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of FerraraGiacomo Chiabrando, Stefano Bianchi, Elisabetta Poluzzi, et al.
Drug Safety|August 31, 2023
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative ApproachValentina Giunchi, Michele Fusaroli, Manfred Hauben, et al.
Basic & Clinical Pharmacology & Toxicology|November 26, 2014
Paraesthesia after local anaesthetics: an analysis of reports to the FDA Adverse Event Reporting SystemCarlo Piccinni, Davide B Gissi, Andrea Gabusi, et al.
Alzheimer'S Research & Therapy|April 11, 2025
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilanceMonia Donati, Angela Boccia, Fabrizio De Ponti, et al.
Breast Cancer Research and Treatment|November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Drug Safety|March 20, 2010
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting SystemElisabetta Poluzzi, Emanuel Raschi, Domenico Motola, et al.
Expert Opinion on Pharmacotherapy|October 10, 2018
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver diseaseEmanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, et al.
Drug Safety|February 20, 2016
Authors' Reply to Alain Braillon's Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project"Emanuel Raschi, Elisabetta Poluzzi, Francesco Salvo, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
BMC Pharmacology & Toxicology|May 6, 2018
Recurrence of pericarditis after influenza vaccination: a case report and review of the literatureRiccardo Mei, Emanuel Raschi, Elisabetta Poluzzi, et al.
Pageof 19

Showing results (31-40 of 189) with videos related to

Sort By:
Pageof 19
European Journal of Clinical Pharmacology|May 14, 2010
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of FerraraGiacomo Chiabrando, Stefano Bianchi, Elisabetta Poluzzi, et al.
Drug Safety|August 31, 2023
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative ApproachValentina Giunchi, Michele Fusaroli, Manfred Hauben, et al.
Basic & Clinical Pharmacology & Toxicology|November 26, 2014
Paraesthesia after local anaesthetics: an analysis of reports to the FDA Adverse Event Reporting SystemCarlo Piccinni, Davide B Gissi, Andrea Gabusi, et al.
Alzheimer'S Research & Therapy|April 11, 2025
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilanceMonia Donati, Angela Boccia, Fabrizio De Ponti, et al.
Breast Cancer Research and Treatment|November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Drug Safety|March 20, 2010
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting SystemElisabetta Poluzzi, Emanuel Raschi, Domenico Motola, et al.
Expert Opinion on Pharmacotherapy|October 10, 2018
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver diseaseEmanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, et al.
Drug Safety|February 20, 2016
Authors' Reply to Alain Braillon's Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project"Emanuel Raschi, Elisabetta Poluzzi, Francesco Salvo, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
BMC Pharmacology & Toxicology|May 6, 2018
Recurrence of pericarditis after influenza vaccination: a case report and review of the literatureRiccardo Mei, Emanuel Raschi, Elisabetta Poluzzi, et al.
Pageof 19